While the broader immuno-oncology space has been dominated by PD-1 and TIGIT inhibitors, Compugen is targeting the under-explored PVRIG pathway with their lead asset COM701. The industry has seen ...

scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.” Roche has another half-dozen phase 3 trials on the go with tiragolumab in other NSCLC settings ...

Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...

and supports the potential therapeutic benefit of inhibiting the TIGIT pathway.” “I was also encouraged by the consistency of meaningful improvements across other outcome measures for the ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Neuroblastoma (NB), the most prevalent extracranial solid tumor among children, is characterized by a high rate of metastasis ...

TIGIT is a checkpoint protein found on immune ... small-molecule therapies aimed at activating innate homeostatic pathways to address metabolic disorders. The company’s lead product, ARD-101 ...

Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a ...